ABBV · News · 20261103N
Licensing / Collaboration Deals
AbbVie Inc. · 2026-11-03 · Importance 38 · Surprise 24 · In source text
AbbVie has a licensing agreement with Brise Pharmaceuticals covering two early-stage migraine drug programs, with payments of up to $757 million. The deal was originally forged in 2024; Brise will lead discovery, while AbbVie will manage global development and commercialization. Brise is eligible for royalties on future sales, and the reported maximum deal value exceeds the materiality threshold.
Key facts
- AbbVie finalized a licensing agreement with Brise Pharmaceuticals worth up to $757 million to develop and commercialize two early-stage migraine drug programs. source
- Under the migraine-program agreement, Brise will lead discovery while AbbVie handles global development and commercialization. source
- Brise will receive royalties on future sales under the migraine-program agreement. source
- The migraine-program deal was originally forged in 2024. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | contingent | -0.0% | AbbVie finalized a licensing agreement with Brise Pharmaceuticals worth up to $757 million to develop and commercialize two early-stage… |